Cafe Au Lait Spots Clinical Presentation

  • Author: William D James, MD; Chief Editor: Dirk M Elston, MD   more...
 
Updated: Aug 1, 2011
 

History

The presence of numerous café au lait macules (CALMs) should raise the suspicion of a genetic disorder. The most common associated systemic disorder is neurofibromatosis type 1 (NF1).

The diagnostic criteria for NF1 are met if 2 or more of the following are present:

  • Six or more café au lait spots larger than 5 mm in greatest diameter in prepubertal individuals and larger than 15 mm in greatest diameter in postpubertal individuals
  • Two or more neurofibromas of any type or 1 plexiform neurofibroma
  • Freckling in the axillary or inguinal regions
  • Optic glioma
  • Two or more Lisch nodules (iris hamartomas)
  • A distinctive osseous lesion, such as sphenoid dysplasia or thinning of the long bone cortex, with or without pseudoarthrosis
  • A first-degree relative with NF1, according to the above criteria

Characteristics of NF1 in the newborn period include the following:

  • Pseudarthroses
  • Congenital glaucoma
  • Sphenoid wing dysplasia

Characteristics of NF1 in the early childhood period include the following:

  • Embryonal tumors
  • Compression injuries: Plexiform neurofibromas in the mediastinal cavity may cause compression. Back pain in a patient with café au lait lesions should always be taken seriously because this symptom may be a sign of a radiculopathy.
  • Optic pathway gliomas: These occur by the time the patient is aged 3 years.

NF1 should be differentiated from neurofibromatosis type 2 (NF2). NF2 is also referred to as central neurofibromatosis because it is associated with acoustic neuroma. Patients with NF2 may also have café au lait macules. NF2 is more likely to be diagnosed in middle-aged persons, unlike NF1, which is typically diagnosed in children. The genes that are responsible for these 2 disorders are on different chromosomes: chromosome 17 in NF1 (encoding neurofibromin) and chromosome 22 in NF2.

Other syndromes associated with café au lait spots include the following:

  • McCune-Albright syndrome: This syndrome often has one large, asymmetric café au lait macule with irregular borders, which is often described as being like the "coast of Maine." The syndrome is associated with polyostotic fibrous dysplasia, which leads to pathologic fractures, precocious puberty, and numerous hyperfunctional endocrinopathies.[5] Early in life, it may present with a single, large irregular café au lait spot. Follow-up observations reveal the endocrine abnormalities.
  • Fanconi anemia: Café au lait macules are present along with mental retardation, aplastic anemia, and risk for malignancy.
  • Tuberous sclerosis: Café au lait spots are present along with Ash leaf spots, facial angiofibromas, hemangiomas, cardiac rhabdomyomas, and shagreen patches.
  • Ataxia telangiectasia
  • Bloom syndrome
  • Basal cell nevus syndrome
  • Chiak-Higashi syndrome
  • Hunter syndrome
  • Maffucci syndrome
  • Multiple mucosal neuroma syndrome
  • Watson syndrome

Whereas small café au lait spots are associated with various syndromes, large, solitary, light-brown patches often represent segmental lentigines that are not associated with any neurocutaneous syndromes or developmental anomalies.

Next

Physical

Café au lait spots are flat lesions that are typically the color made by adding milk to coffee. They may vary in size from a few millimeters, as in axillary freckling, to large macules that measure more than 10 cm in size.

Large, solitary café au lait macules are larger than 0.5 cm. They are found more commonly on the buttocks than any other anatomical location. No other physical findings or syndromes are usually related to solitary CAL spots.

Axillary freckling (known as Crowe sign) and inguinal freckling are characteristic diagnostic features of NF1.

Plexiform neurofibromas may underlie café au lait macules in NF1. These are large fibrous swellings of the subcutaneous tissue that may cause severe disfigurement of the face or limbs.

Café au lait spots are associated with underlying disorders, and physical findings indicative of those disorders include the following:

  • Scoliosis
  • Hypoplastic bowing of the legs
  • Osseous lesions in the ribs
  • Pseudoarthrosis of the tibia
  • Spina bifida
  • Scalloping of the vertebral body
  • Lisch nodules
  • Neurofibromas
  • Lipomata
  • Angiomata
  • Ptosis
  • Ocular abnormalities (including glaucoma and corneal opacifications)
Previous
Next

Causes

Café au lait macules associated with NF1 result from an autosomal dominant disorder with high penetrance and variability in the expression of clinical features.

  • The NF1 gene is localized to the pericentromeric region of the long arm of chromosome 17. The gene encodes for neurofibromin, which is a GTP-ase activating protein that downregulates cellular proto-oncogene, p21-ras.
  • About 50% of individuals with NF1 have a spontaneous mutation. The high incidence of new mutations is thought to result from the large size of the gene, which increases the likelihood of spontaneous mutations.
  • Occasionally, patients who have larger gene deletions have a higher incidence of mental retardation and earlier appearance of cutaneous neurofibromas.
Previous
 
 
Contributor Information and Disclosures
Author

William D James, MD  Paul R Gross Professor of Dermatology, University of Pennsylvania School of Medicine; Vice-Chair, Program Director, Department of Dermatology, University of Pennsylvania Health System

William D James, MD is a member of the following medical societies: American Academy of Dermatology and Society for Investigative Dermatology

Disclosure: Elsevier Royalty Other

Coauthor(s)

Raj D Sheth, MD  Professor, Mayo College of Medicine; Chief, Division of Pediatric Neurology, Nemours Children's Clinic

Raj D Sheth, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Pediatrics, American Epilepsy Society, American Neurological Association, and Child Neurology Society

Disclosure: Nothing to disclose.

Nazanin Saedi, MD  Fellow, SkinCare Physicians, Chestnut Hill, MA

Nazanin Saedi, MD is a member of the following medical societies: American Academy of Dermatology and American Society for Dermatologic Surgery

Disclosure: Nothing to disclose.

Specialty Editor Board

Kevin P Connelly, DO  Clinical Assistant Professor, Department of Pediatrics, Division of General Pediatrics and Emergency Care, Virginia Commonwealth University School of Medicine; Medical Director, Paws for Health Pet Visitation Program of the Richmond SPCA; Pediatric Emergency Physician, Emergency Consultants Inc, Chippenham Medical Center

Kevin P Connelly, DO is a member of the following medical societies: American Academy of Pediatrics, American College of Osteopathic Pediatricians, and American Osteopathic Association

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Robert A Schwartz, MD, MPH  Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi

Disclosure: Nothing to disclose.

Merrily P M Poth, MD  Professor, Department of Pediatrics and Neuroscience, Uniformed Services University of the Health Sciences

Merrily P M Poth, MD is a member of the following medical societies: American Academy of Pediatrics, Endocrine Society, and Pediatric Endocrine Society

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD  Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

References
  1. Plensdorf S, Martinez J. Common pigmentation disorders. Am Fam Physician. Jan 15 2009;79(2):109-16. [Medline].

  2. Abeliovich D, Gelman-Kohan Z, Silverstein S, et al. Familial cafe au lait spots: a variant of neurofibromatosis type 1. J Med Genet. Dec 1995;32(12):985-6. [Medline].

  3. Tekin M, Bodurtha JN, Riccardi VM. Cafe au lait spots: the pediatrician's perspective. Pediatr Rev. Mar 2001;22(3):82-90. [Medline].

  4. De Schepper S, Boucneau J, Vander Haeghen Y, et al. Cafe-au-lait spots in neurofibromatosis type 1 and in healthy control individuals: hyperpigmentation of a different kind?. Arch Dermatol Res. Apr 2006;297(10):439-49. [Medline].

  5. Medina YN, Rapaport R. Evolving diagnosis of McCune-Albright syndrome. atypical presentation and follow up. J Pediatr Endocrinol Metab. Apr 2009;22(4):373-7. [Medline].

  6. [Best Evidence] Polder KD, Landau JM, Vergilis-Kalner IJ, Goldberg LH, Friedman PM, Bruce S. Laser eradication of pigmented lesions: a review. Dermatol Surg. May/2011;37:572-95. [Medline].

  7. Carpo BG, Grevelink JM, Grevelink SV. Laser treatment of pigmented lesions in children. Seminars in Cutaneous Medicine and Surgery. 1999;18:233-243. [Medline].

  8. Stratigos AJ, Dover JS, Arndt KA. Laser treatment of pigmented lesions- 2000: how far have we gone?. Arch Dermatol. 2000;136(7):915-21. [Medline].

  9. Goldberg DJ. Laser treatment of pigmented lesions. Dermatol Clin. 1997;15:397-407. [Medline].

  10. Alora MB, Arndt KA. Treatment of a café-au-lait macule with the erbium:YAG laser. J Am Acad Dermatol. 2001;45:566–8. [Medline].

  11. Alster TS. Complete elimination of large cafe-au-lait birthmarks by the 510-nm pulsed-dye laser. Plast Reconstr Surg. 1995;96:1660-64. [Medline].

  12. [Guideline] Radtke HB, Sebold CD, Allison C, Haidle JL, Schneider G. Neurofibromatosis type 1 in genetic counseling practice: recommendations of the National Society of Genetic Counselors. J Genet Couns. Aug 2007;16(4):387-407. [Medline].

  13. Benedict PH, Szabo G, Fitzpatrick TB, Sinesi SJ. Melanotic macules in Albright's syndrome and in neurofibromatosis. JAMA. Aug 26 1968;205(9):618-26. [Medline].

  14. Cnossen MH, Moons KG, Garssen MP, et al. Minor disease features in neurofibromatosis type 1 (NF1) and their possible value in diagnosis of NF1 in children < or = 6 years and clinically suspected of having NF1. Neurofibromatosis team of Sophia Children's Hospital. J Med Genet. Aug 1998;35(8):624-7. [Medline].

  15. Cohen JB, Janniger CK, Schwartz RA. Cafe-au-lait spots. Cutis. Jul 2000;66(1):22-4. [Medline].

  16. De Schepper S, Boucneau J, Lambert J, et al. Pigment cell-related manifestation in neurofibromatosis type 1: an overview. Pigment Cell Research. 2005;18:13-24. [Medline].

  17. Dohil MA, Baugh WP, Eichenfield LF. Vascular and pigmented birthmarks. Pediatric Clinics of North America. 2000;47:783-812. [Medline].

  18. Eichenfield LF, Gibbs NF. Hyperpigmentation disorders. In: Textbook of Neonatal Dermatology. 2000:370.

  19. Friedman JM. Epidemiology of neurofibromatosis type 1. Am J Med Genet. Mar 26 1999;89(1):1-6. [Medline].

  20. Friedman JM, Birch PH. Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. Am J Med Genet. May 16 1997;70(2):138-43. [Medline].

  21. Hofman KJ, Boehm CD. Familial neurofibromatosis type 1: clinical experience with DNA testing. J Pediatr. Mar 1992;120(3):394-8. [Medline].

  22. Hofman KJ, Harris EL, Bryan RN, Denckla MB. Neurofibromatosis type 1: the cognitive phenotype. J Pediatr. Apr 1994;124(4):S1-8. [Medline].

  23. Johnson BL, Charneco DR. Cafe au lait spot in neurofibromatosis and in normal individuals. Arch Dermatol. Oct 1970;102(4):442-6. [Medline].

  24. Legius E, Descheemaeker MJ, Steyaert J, et al. Neurofibromatosis type 1 in childhood: correlation of MRI findings with intelligence. J Neurol Neurosurg Psychiatry. Dec 1995;59(6):638-40. [Medline].

  25. Listernick R, Darling C, Greenwald M, et al. Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history. J Pediatr. Nov 1995;127(5):718-22. [Medline].

  26. Nguyen JT, Yan AC, James WD. Large solitary cafe au lait spots: a report of 5 cases and review of the literature. Cutis. May 2004;73(5):311-4, 316. [Medline].

  27. Orion E, Matz H, Wolf D, Wolf R. Cafe au lait has hue of its own. Dermatology Online Journal. 2003;9:8. [Medline].

  28. Pinson S, Wolkenstein P. Neurofibromatosis type 1 or Von Recklinghausen's disease. La Revue de Medecine Interne. 2005;26:196-215. [Medline].

  29. Ruggieri M, Huson SM. The neurofibromatoses. An overview. Ital J Neurol Sci. Apr 1999;20(2):89-108. [Medline].

  30. Thami GP, Garg G. Cafe-au-lait macules: are these markers of neoplasia of genetic origin?. Dermatology. 2004;208:234-5. [Medline].

  31. Ward BA, Gutamann DH. Neurofibromatosis 1: From lab bench to clinic. Pediatric Neurology. 2005;32:221-228. [Medline].

Previous
Next
 
Axillary freckling showing café au lait spots.
Multiple irregular sized and shaped café au lait lesions.
Café au lait lesions.
Café au lait lesions.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.